Nanoantibiotics to fight multidrug resistant infections by Gram-positive bacteria: hope or reality?

Berini, Francesca; Orlandi, Viviana Teresa; Gornati, Rosalba; Bernardini, Giovanni; Marinelli, Flavia

doi:10.1016/j.biotechadv.2022.107948

Cited by 29 publications

(13 citation statements)

References 253 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, the antibacterial drug Fetroja (Shionogi & Co.) got approval from FDA for the treatment of gram-negative bacteria-mediated cUTI in patients having limited treatment options due to hypersensitive history. The list of antibiotics currently in the phase of clinical development against various critical superbugs is summarized in Table 5 [67][68][69][70][71][72][73][74][75][76][77][78][79][80][81][82][83][84][85].…”

Section: Approved/pipeline Drugs Against Critical Superbugsmentioning

confidence: 99%

Current Treatment Strategies Against Multidrug-Resistant Bacteria: A Review

et al. 2022

View full text Add to dashboard Cite

There are several bacteria called superbugs that are resistant to multiple antibiotics which can be life threatening specially for critically ill and hospitalized patients. This article provides up-to-date treatment strategies employed against some major superbugs, like methicillin-resistant Staphylococcus aureus, carbapenem-resistant Enterobacteriaceae, vancomycin-resistant Enterococcus, multidrug-resistant Pseudomonas aeruginosa, and multidrug-resistant Escherichia coli. The pathogen-directed therapeutics decrease the toxicity of bacteria by altering their virulence factors by specific processes. On the other hand, the host-directed therapeutics limits these superbugs by modulating immune cells, enhancing host cell functions, and modifying disease pathology. Several new antibiotics against the global priority superbugs are coming to the market or are in the clinical development phase. Medicinal plants possessing potent secondary metabolites can play a key role in the treatment against these superbugs. Nanotechnology has also emerged as a promising option for combatting them. There is urgent need to continuously figure out the best possible treatment strategy against these superbugs as resistance can also be developed against the new and upcoming antibiotics in future. Rational use of antibiotics and maintenance of proper hygiene must be practiced among patients.

show abstract

Section: Approved/pipeline Drugs Against Critical Superbugsmentioning

confidence: 99%

Current Treatment Strategies Against Multidrug-Resistant Bacteria: A Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Given the emergence of multidrug-resistant bacterial strains, which has severely decreased the efficacy of antibiotic treatments, the need for new strategies for biofilm prevention and disruption is continuously increasing. Recently, the potential to exploit nanoparticles (NPs) for biofilm control and eradication has been a growing interest among the scientific community. , …”

Section: Introductionmentioning

confidence: 99%

“…Recently, the potential to exploit nanoparticles (NPs) for biofilm control and eradication has been a growing interest among the scientific community. 4,5 Different families of nanomaterials and NPs have been considered as promising antimicrobial and antibiofilm agents, and evidence of antibacterial effects has already been demonstrated for various chemical compositions (Ag, ZnO, Au, and chitosan), surface modification 6,7 and morphology. 8 While many studies in the literature point out that NPs showing antibacterial action most likely interfere with bacterial metabolism and cellular membranes, 3 what is not yet fully understood is the role of the EPS in the general framework of NP−biofilm interactions.…”

Section: ■ Introductionmentioning

confidence: 99%

Interaction between Engineered Pluronic Silica Nanoparticles and Bacterial Biofilms: Elucidating the Role of Nanoparticle Surface Chemistry and EPS Matrix

Vitale

Rampazzo

Hiebner

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Nanoparticles (NPs) are considered a promising tool in the context of biofilm control. Many studies have shown that different types of NPs can interfere with the bacterial metabolism and cellular membranes, thus making them potential antibacterial agents; however, fundamental understanding is still lacking on the exact mechanisms involved in these actions. The development of NP-based approaches for effective biofilm control also requires a thorough understanding of how the chosen nanoparticles will interact with the biofilm itself, and in particular with the biofilm self-produced extracellular polymeric matrix (EPS). This work aims to provide advances in the understanding of the interaction between engineered fluorescent pluronic silica (PluS) nanoparticles and bacterial biofilms, with a main focus on the role of the EPS matrix in the accumulation and diffusion of the particles in the biofilm. It is demonstrated that particle surface chemistry has a key role in the different lateral distribution and specific affinity to the biofilm matrix components. The results presented in this study contribute to our understanding of biofilm–NP interactions and promote the principle of the rational design of smart nanoparticles as an important tool for antibiofilm technology.

show abstract

“…For this reason, antimicrobial chemotherapy, specifically selected using antibiogram, is commonly recommend and systemic administration via parenteral or oral routes is required to reduce the risk of antibiotic resistance (AMR). In fact, AMR represents one of the greatest threats to human health, causing morbidity and mortality worldwide and high management cost-related [ 7 ]. A recent report estimated that infections by multidrug and drug-resistant bacteria caused in 2019 the death of 1.27 million people and if specific actions are not urgently taken, this number is projected to increase to ten million by 2050, thus overcoming the deaths caused by road accidents, diabetes, or cancer [ 8 ].…”

Section: Introductionmentioning

confidence: 99%